Metabolomics for Early-stage Lung Adenocarcinoma

We performed untargeted metabolomics study, and divided participants into four groups: early-stage lung adenocarcinoma group (E-LUAD, n=21), healthy control group(HC, n=17), noncancerous lung diseases group (NCC, n=17), and advanced lung adenocarcinoma group (A-LUAD, n=25). Plasma metabolite levels that differed in the E-LUAD group compared to the other three groups were identified by liquid chromatography-mass spectrometry (LC-MS).